ES2376176T3 - Compuestos y procedimientos para modular fxr. - Google Patents
Compuestos y procedimientos para modular fxr. Download PDFInfo
- Publication number
- ES2376176T3 ES2376176T3 ES08781651T ES08781651T ES2376176T3 ES 2376176 T3 ES2376176 T3 ES 2376176T3 ES 08781651 T ES08781651 T ES 08781651T ES 08781651 T ES08781651 T ES 08781651T ES 2376176 T3 ES2376176 T3 ES 2376176T3
- Authority
- ES
- Spain
- Prior art keywords
- phenyl
- isoxazol
- cyclopropyl
- dichloro
- ylmethoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 241
- 238000000034 method Methods 0.000 title description 31
- -1 benzoisothiazolyl Chemical group 0.000 claims abstract description 68
- 150000003839 salts Chemical class 0.000 claims abstract description 15
- 239000000460 chlorine Substances 0.000 claims abstract description 14
- 229910052801 chlorine Inorganic materials 0.000 claims abstract description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 10
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims abstract description 10
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 9
- 239000001257 hydrogen Substances 0.000 claims abstract description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 9
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims abstract description 8
- 125000001309 chloro group Chemical group Cl* 0.000 claims abstract description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 7
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims abstract description 6
- 125000001153 fluoro group Chemical group F* 0.000 claims abstract description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims abstract description 5
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims abstract description 3
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims abstract description 3
- 125000001041 indolyl group Chemical group 0.000 claims abstract description 3
- 125000001624 naphthyl group Chemical group 0.000 claims abstract description 3
- 125000004076 pyridyl group Chemical group 0.000 claims abstract description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 3
- 239000002253 acid Substances 0.000 claims description 24
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 14
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 11
- RPVDFHPBGBMWID-UHFFFAOYSA-N 6-[4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]piperidin-1-yl]-1-methylindole-3-carboxylic acid Chemical compound C1=C2N(C)C=C(C(O)=O)C2=CC=C1N(CC1)CCC1OCC1=C(C2CC2)ON=C1C1=C(Cl)C=CC=C1Cl RPVDFHPBGBMWID-UHFFFAOYSA-N 0.000 claims description 7
- BHHQDQJNIROKNF-UHFFFAOYSA-N 4-[4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]azepan-1-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1N1CCC(OCC=2C(=NOC=2C2CC2)C=2C(=CC=CC=2Cl)Cl)CCC1 BHHQDQJNIROKNF-UHFFFAOYSA-N 0.000 claims description 6
- FMYIBSTZKZVLRS-UHFFFAOYSA-N 4-[4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]cyclohexyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1CCC(OCC=2C(=NOC=2C2CC2)C=2C(=CC=CC=2Cl)Cl)CC1 FMYIBSTZKZVLRS-UHFFFAOYSA-N 0.000 claims description 5
- QEPDFQBZEHAKMC-UHFFFAOYSA-N 6-[4-[[3-(2,6-dichlorophenyl)-5-propan-2-yl-1,2-oxazol-4-yl]methoxy]piperidin-1-yl]-1-methylindole-3-carboxylic acid Chemical compound C1CN(C=2C=C3N(C)C=C(C3=CC=2)C(O)=O)CCC1OCC1=C(C(C)C)ON=C1C1=C(Cl)C=CC=C1Cl QEPDFQBZEHAKMC-UHFFFAOYSA-N 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- FXODJZPFWQPPDM-UHFFFAOYSA-N 4-[4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]piperidin-1-yl]-2-phenylbenzoic acid Chemical compound OC(=O)C1=CC=C(N2CCC(CC2)OCC=2C(=NOC=2C2CC2)C=2C(=CC=CC=2Cl)Cl)C=C1C1=CC=CC=C1 FXODJZPFWQPPDM-UHFFFAOYSA-N 0.000 claims description 3
- VXDXGDBJVDCGPS-UHFFFAOYSA-N 6-[4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]azepan-1-yl]-1-methylindole-3-carboxylic acid Chemical compound C1=C2N(C)C=C(C(O)=O)C2=CC=C1N(CC1)CCCC1OCC1=C(C2CC2)ON=C1C1=C(Cl)C=CC=C1Cl VXDXGDBJVDCGPS-UHFFFAOYSA-N 0.000 claims description 3
- BMHSHVMYWHJZHM-UHFFFAOYSA-N 4-[4-[[3-(2,6-dichlorophenyl)-5-propan-2-yl-1,2-oxazol-4-yl]methoxy]piperidin-1-yl]-2-methylbenzoic acid Chemical compound CC(C)C=1ON=C(C=2C(=CC=CC=2Cl)Cl)C=1COC(CC1)CCN1C1=CC=C(C(O)=O)C(C)=C1 BMHSHVMYWHJZHM-UHFFFAOYSA-N 0.000 claims description 2
- OLWQNBCXCFTKAN-UHFFFAOYSA-N 4-[4-[[3-(2,6-dichlorophenyl)-5-propan-2-yl-1,2-oxazol-4-yl]methoxy]piperidin-1-yl]-2-phenylbenzoic acid Chemical compound CC(C)C=1ON=C(C=2C(=CC=CC=2Cl)Cl)C=1COC(CC1)CCN1C(C=1)=CC=C(C(O)=O)C=1C1=CC=CC=C1 OLWQNBCXCFTKAN-UHFFFAOYSA-N 0.000 claims description 2
- TUXQDUMYSZHKDF-UHFFFAOYSA-N 4-[4-[[3-(2,6-dichlorophenyl)-5-propan-2-yl-1,2-oxazol-4-yl]methoxy]piperidin-1-yl]-3-methylbenzoic acid Chemical compound CC(C)C=1ON=C(C=2C(=CC=CC=2Cl)Cl)C=1COC(CC1)CCN1C1=CC=C(C(O)=O)C=C1C TUXQDUMYSZHKDF-UHFFFAOYSA-N 0.000 claims description 2
- SARVSQBHGLWJDC-UHFFFAOYSA-N 4-[4-[[3-(2,6-dichlorophenyl)-5-propan-2-yl-1,2-oxazol-4-yl]methoxy]piperidin-1-yl]benzoic acid Chemical compound CC(C)C=1ON=C(C=2C(=CC=CC=2Cl)Cl)C=1COC(CC1)CCN1C1=CC=C(C(O)=O)C=C1 SARVSQBHGLWJDC-UHFFFAOYSA-N 0.000 claims description 2
- LTQORJNFRTWNQZ-UHFFFAOYSA-N 4-[4-[[3-(2,6-dichlorophenyl)-5-propan-2-yl-1,2-oxazol-4-yl]methoxy]piperidin-1-yl]naphthalene-1-carboxylic acid Chemical compound C1CN(C=2C3=CC=CC=C3C(C(O)=O)=CC=2)CCC1OCC1=C(C(C)C)ON=C1C1=C(Cl)C=CC=C1Cl LTQORJNFRTWNQZ-UHFFFAOYSA-N 0.000 claims description 2
- KMAPTVZHJWJUDZ-UHFFFAOYSA-N 4-[4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]piperidin-1-yl]-2-methylbenzoic acid Chemical compound C1=C(C(O)=O)C(C)=CC(N2CCC(CC2)OCC=2C(=NOC=2C2CC2)C=2C(=CC=CC=2Cl)Cl)=C1 KMAPTVZHJWJUDZ-UHFFFAOYSA-N 0.000 claims description 2
- ZPNMRIMLACQTND-UHFFFAOYSA-N 4-[4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]piperidin-1-yl]-3-methylbenzoic acid Chemical compound CC1=CC(C(O)=O)=CC=C1N1CCC(OCC=2C(=NOC=2C2CC2)C=2C(=CC=CC=2Cl)Cl)CC1 ZPNMRIMLACQTND-UHFFFAOYSA-N 0.000 claims description 2
- JDPVTPAYEUGANP-UHFFFAOYSA-N 4-[4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]piperidin-1-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1N1CCC(OCC=2C(=NOC=2C2CC2)C=2C(=CC=CC=2Cl)Cl)CC1 JDPVTPAYEUGANP-UHFFFAOYSA-N 0.000 claims description 2
- YLOIALRDPVKHBC-UHFFFAOYSA-N 4-[4-[[5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl]methoxy]piperidin-1-yl]-2-methylbenzoic acid Chemical compound C1=C(C(O)=O)C(C)=CC(N2CCC(CC2)OCC=2C(=NOC=2C2CC2)C=2C(=CC=CC=2)OC(F)(F)F)=C1 YLOIALRDPVKHBC-UHFFFAOYSA-N 0.000 claims description 2
- ITMGGFXMTLJIBH-UHFFFAOYSA-N 4-[4-[[5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl]methoxy]piperidin-1-yl]-2-phenylbenzoic acid Chemical compound OC(=O)C1=CC=C(N2CCC(CC2)OCC=2C(=NOC=2C2CC2)C=2C(=CC=CC=2)OC(F)(F)F)C=C1C1=CC=CC=C1 ITMGGFXMTLJIBH-UHFFFAOYSA-N 0.000 claims description 2
- UVERNCKJGPCBJN-UHFFFAOYSA-N 4-[4-[[5-propan-2-yl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl]methoxy]piperidin-1-yl]benzoic acid Chemical compound CC(C)C=1ON=C(C=2C(=CC=CC=2)OC(F)(F)F)C=1COC(CC1)CCN1C1=CC=C(C(O)=O)C=C1 UVERNCKJGPCBJN-UHFFFAOYSA-N 0.000 claims description 2
- QYHGTOWHHXVPJY-UHFFFAOYSA-N 6-[4-[[3-(2,6-dichlorophenyl)-5-propan-2-yl-1,2-oxazol-4-yl]methoxy]piperidin-1-yl]-1-benzothiophene-3-carboxylic acid Chemical compound C1CN(C=2C=C3SC=C(C3=CC=2)C(O)=O)CCC1OCC1=C(C(C)C)ON=C1C1=C(Cl)C=CC=C1Cl QYHGTOWHHXVPJY-UHFFFAOYSA-N 0.000 claims description 2
- QVSRRDPHMZENOC-UHFFFAOYSA-N 6-[4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]azepan-1-yl]-1-benzothiophene-3-carboxylic acid Chemical compound C=1C=C2C(C(=O)O)=CSC2=CC=1N(CC1)CCCC1OCC1=C(C2CC2)ON=C1C1=C(Cl)C=CC=C1Cl QVSRRDPHMZENOC-UHFFFAOYSA-N 0.000 claims description 2
- GAPDATOJAODWBF-UHFFFAOYSA-N 6-[4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]piperidin-1-yl]-1-benzothiophene-3-carboxylic acid Chemical compound C=1C=C2C(C(=O)O)=CSC2=CC=1N(CC1)CCC1OCC1=C(C2CC2)ON=C1C1=C(Cl)C=CC=C1Cl GAPDATOJAODWBF-UHFFFAOYSA-N 0.000 claims description 2
- GWXYJEDUVAMRFV-UHFFFAOYSA-N 6-[4-[[5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl]methoxy]piperidin-1-yl]-1-methylindole-3-carboxylic acid Chemical compound C1=C2N(C)C=C(C(O)=O)C2=CC=C1N(CC1)CCC1OCC1=C(C2CC2)ON=C1C1=CC=CC=C1OC(F)(F)F GWXYJEDUVAMRFV-UHFFFAOYSA-N 0.000 claims description 2
- GMKJZUNUHWUPRV-IRJFHVNHSA-N Cn1cc(C(O)=O)c2ccc(cc12)[C@H]1CC[C@@H](CC1)OCc1c(onc1-c1ccccc1OC(F)(F)F)C1CC1 Chemical compound Cn1cc(C(O)=O)c2ccc(cc12)[C@H]1CC[C@@H](CC1)OCc1c(onc1-c1ccccc1OC(F)(F)F)C1CC1 GMKJZUNUHWUPRV-IRJFHVNHSA-N 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- KLKSMSZZLBFWCT-IRJFHVNHSA-N OC(=O)c1ccc(cc1)[C@H]1CC[C@@H](CC1)OCc1c(onc1-c1ccccc1OC(F)(F)F)C1CC1 Chemical compound OC(=O)c1ccc(cc1)[C@H]1CC[C@@H](CC1)OCc1c(onc1-c1ccccc1OC(F)(F)F)C1CC1 KLKSMSZZLBFWCT-IRJFHVNHSA-N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 290
- 239000000203 mixture Substances 0.000 description 125
- 238000002360 preparation method Methods 0.000 description 119
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 114
- 235000019439 ethyl acetate Nutrition 0.000 description 114
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 110
- 239000000243 solution Substances 0.000 description 110
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 104
- 239000007787 solid Substances 0.000 description 94
- 239000000543 intermediate Substances 0.000 description 92
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 89
- 229910001868 water Inorganic materials 0.000 description 75
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 74
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 64
- 238000006243 chemical reaction Methods 0.000 description 63
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 54
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 54
- 239000011541 reaction mixture Substances 0.000 description 52
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 46
- 239000012074 organic phase Substances 0.000 description 43
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 40
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 39
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 38
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 38
- 239000012267 brine Substances 0.000 description 35
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 35
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 34
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 33
- 239000002904 solvent Substances 0.000 description 32
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 30
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 29
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 28
- 239000000725 suspension Substances 0.000 description 28
- 239000012071 phase Substances 0.000 description 27
- 229910052938 sodium sulfate Inorganic materials 0.000 description 25
- 235000011152 sodium sulphate Nutrition 0.000 description 25
- 239000007858 starting material Substances 0.000 description 24
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 23
- 238000003818 flash chromatography Methods 0.000 description 20
- 239000000741 silica gel Substances 0.000 description 20
- 229910002027 silica gel Inorganic materials 0.000 description 20
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 19
- 235000019341 magnesium sulphate Nutrition 0.000 description 19
- 239000008346 aqueous phase Substances 0.000 description 18
- 239000000377 silicon dioxide Substances 0.000 description 18
- 238000005160 1H NMR spectroscopy Methods 0.000 description 17
- 239000007832 Na2SO4 Substances 0.000 description 17
- 239000012043 crude product Substances 0.000 description 17
- 238000001914 filtration Methods 0.000 description 17
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 15
- 239000012299 nitrogen atmosphere Substances 0.000 description 15
- 239000003921 oil Substances 0.000 description 15
- 235000019198 oils Nutrition 0.000 description 15
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- 239000000706 filtrate Substances 0.000 description 14
- 229910000027 potassium carbonate Inorganic materials 0.000 description 14
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 12
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 12
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 12
- SKZJYJMYLUQJPG-UHFFFAOYSA-N methyl 6-bromo-1h-indole-3-carboxylate Chemical class BrC1=CC=C2C(C(=O)OC)=CNC2=C1 SKZJYJMYLUQJPG-UHFFFAOYSA-N 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 11
- 235000012000 cholesterol Nutrition 0.000 description 11
- 238000004587 chromatography analysis Methods 0.000 description 11
- 239000012065 filter cake Substances 0.000 description 11
- 238000010992 reflux Methods 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 10
- 150000002148 esters Chemical class 0.000 description 10
- PNZIYSWKRBYITO-UHFFFAOYSA-N 4-(bromomethyl)-5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazole Chemical compound ClC1=CC=CC(Cl)=C1C1=NOC(C2CC2)=C1CBr PNZIYSWKRBYITO-UHFFFAOYSA-N 0.000 description 9
- INNZWYJJSSRJET-UHFFFAOYSA-N 6-bromo-1h-indole-3-carboxylic acid Chemical compound BrC1=CC=C2C(C(=O)O)=CNC2=C1 INNZWYJJSSRJET-UHFFFAOYSA-N 0.000 description 9
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 9
- 239000000284 extract Substances 0.000 description 9
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 9
- XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 8
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- KRGFOUGVZFEEBW-UHFFFAOYSA-N [5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methanol Chemical compound OCC1=C(C2CC2)ON=C1C1=C(Cl)C=CC=C1Cl KRGFOUGVZFEEBW-UHFFFAOYSA-N 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 8
- 238000005859 coupling reaction Methods 0.000 description 7
- IPBRHVDRTRBACF-UHFFFAOYSA-N methyl 5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazole-4-carboxylate Chemical compound COC(=O)C1=C(C2CC2)ON=C1C1=C(Cl)C=CC=C1Cl IPBRHVDRTRBACF-UHFFFAOYSA-N 0.000 description 7
- RLMWPNDSVWJWHA-UHFFFAOYSA-N methyl 6-bromo-1-methylindole-3-carboxylate Chemical compound BrC1=CC=C2C(C(=O)OC)=CN(C)C2=C1 RLMWPNDSVWJWHA-UHFFFAOYSA-N 0.000 description 7
- YBSXDWIAUZOFFV-UHFFFAOYSA-N n-[(2,6-dichlorophenyl)methylidene]hydroxylamine Chemical compound ON=CC1=C(Cl)C=CC=C1Cl YBSXDWIAUZOFFV-UHFFFAOYSA-N 0.000 description 7
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 108010010234 HDL Lipoproteins Proteins 0.000 description 6
- 102000015779 HDL Lipoproteins Human genes 0.000 description 6
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 6
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 6
- 201000001320 Atherosclerosis Diseases 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 5
- 239000005909 Kieselgur Substances 0.000 description 5
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 5
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 5
- 235000019270 ammonium chloride Nutrition 0.000 description 5
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 5
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 5
- 229910000024 caesium carbonate Inorganic materials 0.000 description 5
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 5
- 238000010511 deprotection reaction Methods 0.000 description 5
- 125000004494 ethyl ester group Chemical group 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 5
- 150000004702 methyl esters Chemical class 0.000 description 5
- 238000010898 silica gel chromatography Methods 0.000 description 5
- 239000012312 sodium hydride Substances 0.000 description 5
- 229910000104 sodium hydride Inorganic materials 0.000 description 5
- VNFWTIYUKDMAOP-UHFFFAOYSA-N sphos Chemical compound COC1=CC=CC(OC)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 VNFWTIYUKDMAOP-UHFFFAOYSA-N 0.000 description 5
- 150000003626 triacylglycerols Chemical class 0.000 description 5
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 5
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 4
- DMIYKWPEFRFTPY-UHFFFAOYSA-N 2,6-dichlorobenzaldehyde Chemical compound ClC1=CC=CC(Cl)=C1C=O DMIYKWPEFRFTPY-UHFFFAOYSA-N 0.000 description 4
- BYRWOSJFHWKXET-UHFFFAOYSA-N 2-azido-1,3-dichlorobenzene Chemical compound ClC1=CC=CC(Cl)=C1N=[N+]=[N-] BYRWOSJFHWKXET-UHFFFAOYSA-N 0.000 description 4
- HWBMHQHCLGJHBY-UHFFFAOYSA-N 4-(azepan-4-yloxymethyl)-5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazole Chemical compound ClC1=CC=CC(Cl)=C1C1=NOC(C2CC2)=C1COC1CCNCCC1 HWBMHQHCLGJHBY-UHFFFAOYSA-N 0.000 description 4
- WQOFPZFDXPHYLX-UHFFFAOYSA-N 5-cyclopropyl-3-(2,6-dichlorophenyl)-4-(piperidin-4-yloxymethyl)-1,2-oxazole Chemical compound ClC1=CC=CC(Cl)=C1C1=NOC(C2CC2)=C1COC1CCNCC1 WQOFPZFDXPHYLX-UHFFFAOYSA-N 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- PKKUSJHPTIAISL-JIBACQESSA-N COc1ccc(COc2ccc(cc2)[C@H]2CC[C@@H](CC2)OCc2c(onc2-c2c(Cl)cccc2Cl)C2CC2)cc1 Chemical compound COc1ccc(COc2ccc(cc2)[C@H]2CC[C@@H](CC2)OCc2c(onc2-c2c(Cl)cccc2Cl)C2CC2)cc1 PKKUSJHPTIAISL-JIBACQESSA-N 0.000 description 4
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 4
- 108010007622 LDL Lipoproteins Proteins 0.000 description 4
- 102000007330 LDL Lipoproteins Human genes 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 235000019502 Orange oil Nutrition 0.000 description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 4
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 4
- BHOADJCKTMZNDA-UHFFFAOYSA-N [(2,5-dichlorophenyl)methylideneamino] hypochlorite Chemical compound ClON=CC1=CC(Cl)=CC=C1Cl BHOADJCKTMZNDA-UHFFFAOYSA-N 0.000 description 4
- OUKZIJKCWIBRKF-UHFFFAOYSA-N [(2,6-dichlorophenyl)methylideneamino] hypochlorite Chemical compound ClON=CC1=C(Cl)C=CC=C1Cl OUKZIJKCWIBRKF-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 4
- 239000013058 crude material Substances 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 150000002545 isoxazoles Chemical class 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 239000010502 orange oil Substances 0.000 description 4
- 150000003109 potassium Chemical class 0.000 description 4
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 4
- 229960002429 proline Drugs 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- QCFAVGSPZAPIAL-UHFFFAOYSA-N tert-butyl 4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]azepane-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCCC1OCC1=C(C2CC2)ON=C1C1=C(Cl)C=CC=C1Cl QCFAVGSPZAPIAL-UHFFFAOYSA-N 0.000 description 4
- CRFSWDBNKHNGGA-UHFFFAOYSA-N tert-butyl 4-hydroxyazepane-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC(O)CC1 CRFSWDBNKHNGGA-UHFFFAOYSA-N 0.000 description 4
- PMLBUVZPRKXMOX-UHFFFAOYSA-N tert-butyl 4-oxoazepane-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC(=O)CC1 PMLBUVZPRKXMOX-UHFFFAOYSA-N 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 101001051093 Homo sapiens Low-density lipoprotein receptor Proteins 0.000 description 3
- 102000004895 Lipoproteins Human genes 0.000 description 3
- 108090001030 Lipoproteins Proteins 0.000 description 3
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 3
- QPJVMBTYPHYUOC-UHFFFAOYSA-N Methyl benzoate Natural products COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 3
- PHSPJQZRQAJPPF-UHFFFAOYSA-N N-alpha-Methylhistamine Chemical compound CNCCC1=CN=CN1 PHSPJQZRQAJPPF-UHFFFAOYSA-N 0.000 description 3
- IXHAOUISOMBVMP-RUCARUNLSA-N Oc1ccc(cc1)[C@H]1CC[C@@H](CC1)OCc1c(onc1-c1c(Cl)cccc1Cl)C1CC1 Chemical compound Oc1ccc(cc1)[C@H]1CC[C@@H](CC1)OCc1c(onc1-c1c(Cl)cccc1Cl)C1CC1 IXHAOUISOMBVMP-RUCARUNLSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- GMHPWGYTSXHHPI-UHFFFAOYSA-N azepan-4-one Chemical compound O=C1CCCNCC1 GMHPWGYTSXHHPI-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012230 colorless oil Substances 0.000 description 3
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 3
- 239000012972 dimethylethanolamine Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940121360 farnesoid X receptor (fxr) agonists Drugs 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 150000004820 halides Chemical class 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- LCKHVCZPHZSAAZ-UHFFFAOYSA-N methyl 2-bromo-4-(4-hydroxypiperidin-1-yl)benzoate Chemical compound C1=C(Br)C(C(=O)OC)=CC=C1N1CCC(O)CC1 LCKHVCZPHZSAAZ-UHFFFAOYSA-N 0.000 description 3
- JENBPOJAZCPSEW-UHFFFAOYSA-N methyl 2-bromo-4-fluorobenzoate Chemical compound COC(=O)C1=CC=C(F)C=C1Br JENBPOJAZCPSEW-UHFFFAOYSA-N 0.000 description 3
- 229940095102 methyl benzoate Drugs 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 description 3
- 150000003053 piperidines Chemical class 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 230000004224 protection Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 235000009518 sodium iodide Nutrition 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 3
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 3
- 238000003828 vacuum filtration Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- OQFJHFARLPFNBK-UHFFFAOYSA-N 4-(bromomethyl)-3-(2,6-dichlorophenyl)-5-propan-2-yl-1,2-oxazole Chemical compound BrCC1=C(C(C)C)ON=C1C1=C(Cl)C=CC=C1Cl OQFJHFARLPFNBK-UHFFFAOYSA-N 0.000 description 2
- YFHLGFKXKKEVMB-UHFFFAOYSA-N 4-(bromomethyl)-5-propan-2-yl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazole Chemical compound BrCC1=C(C(C)C)ON=C1C1=CC=CC=C1OC(F)(F)F YFHLGFKXKKEVMB-UHFFFAOYSA-N 0.000 description 2
- CPEPZCYJSJQPRJ-UHFFFAOYSA-N 4-[4-[(4-methoxyphenyl)methoxy]phenyl]cyclohexan-1-ol Chemical compound C1=CC(OC)=CC=C1COC1=CC=C(C2CCC(O)CC2)C=C1 CPEPZCYJSJQPRJ-UHFFFAOYSA-N 0.000 description 2
- BCJVBDBJSMFBRW-UHFFFAOYSA-N 4-diphenylphosphanylbutyl(diphenyl)phosphane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCCP(C=1C=CC=CC=1)C1=CC=CC=C1 BCJVBDBJSMFBRW-UHFFFAOYSA-N 0.000 description 2
- BKAJNAXTPSGJCU-UHFFFAOYSA-N 4-methyl-2-oxopentanoic acid Chemical compound CC(C)CC(=O)C(O)=O BKAJNAXTPSGJCU-UHFFFAOYSA-N 0.000 description 2
- NUAUSXQFDIQJAL-UHFFFAOYSA-N 5-(bromomethyl)-1-(2,6-dichlorophenyl)-4-propan-2-ylpyrazole Chemical compound BrCC1=C(C(C)C)C=NN1C1=C(Cl)C=CC=C1Cl NUAUSXQFDIQJAL-UHFFFAOYSA-N 0.000 description 2
- REUNERYWDIGVGK-UHFFFAOYSA-N 5-(bromomethyl)-1-(2,6-dichlorophenyl)-4-propan-2-yltriazole Chemical compound BrCC1=C(C(C)C)N=NN1C1=C(Cl)C=CC=C1Cl REUNERYWDIGVGK-UHFFFAOYSA-N 0.000 description 2
- JUJOGFIKWWAZQY-UHFFFAOYSA-N 5-cyclopropyl-3-(2,6-dichlorophenyl)-4-(piperidin-4-yloxymethyl)-1,2-oxazole;hydrochloride Chemical compound Cl.ClC1=CC=CC(Cl)=C1C1=NOC(C2CC2)=C1COC1CCNCC1 JUJOGFIKWWAZQY-UHFFFAOYSA-N 0.000 description 2
- OQIMJOXSDVGEBU-UHFFFAOYSA-N 6-bromo-1-benzothiophene Chemical compound BrC1=CC=C2C=CSC2=C1 OQIMJOXSDVGEBU-UHFFFAOYSA-N 0.000 description 2
- ZXMDECZLLPFSJO-UHFFFAOYSA-N 6-bromo-1-benzothiophene-3-carboxylic acid Chemical compound BrC1=CC=C2C(C(=O)O)=CSC2=C1 ZXMDECZLLPFSJO-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- VBNWPEUOYYXUKO-IRJFHVNHSA-N COC(=O)c1ccc(cc1)[C@H]1CC[C@@H](CC1)OCc1c(onc1-c1c(Cl)cccc1Cl)C1CC1 Chemical compound COC(=O)c1ccc(cc1)[C@H]1CC[C@@H](CC1)OCc1c(onc1-c1c(Cl)cccc1Cl)C1CC1 VBNWPEUOYYXUKO-IRJFHVNHSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- WMIORAUDPMUTBF-UHFFFAOYSA-N Cc1cc(ccc1C(O)=O)N1CCCC(CC1)OCc1c(onc1-c1c(Cl)cccc1Cl)C1CC1 Chemical compound Cc1cc(ccc1C(O)=O)N1CCCC(CC1)OCc1c(onc1-c1c(Cl)cccc1Cl)C1CC1 WMIORAUDPMUTBF-UHFFFAOYSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 238000008214 LDL Cholesterol Methods 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 108090001146 Nuclear Receptor Coactivator 1 Proteins 0.000 description 2
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 2
- 102100037223 Nuclear receptor coactivator 1 Human genes 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 229910020667 PBr3 Inorganic materials 0.000 description 2
- 108091027981 Response element Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- YJACSXDQVQCNPU-UHFFFAOYSA-N [2-(2,6-dichlorophenyl)-4-propan-2-ylpyrazol-3-yl]methanol Chemical compound OCC1=C(C(C)C)C=NN1C1=C(Cl)C=CC=C1Cl YJACSXDQVQCNPU-UHFFFAOYSA-N 0.000 description 2
- QKFSDLYZZTWMQG-UHFFFAOYSA-N [3-(2,6-dichlorophenyl)-5-propan-2-yl-1,2-oxazol-4-yl]methanol Chemical compound OCC1=C(C(C)C)ON=C1C1=C(Cl)C=CC=C1Cl QKFSDLYZZTWMQG-UHFFFAOYSA-N 0.000 description 2
- YJPRZVHHSVCUIU-UHFFFAOYSA-N [5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl]methanol Chemical compound OCC1=C(C2CC2)ON=C1C1=CC=CC=C1OC(F)(F)F YJPRZVHHSVCUIU-UHFFFAOYSA-N 0.000 description 2
- NDRQXCRSOHVZSH-UHFFFAOYSA-N [5-propan-2-yl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl]methanol Chemical compound OCC1=C(C(C)C)ON=C1C1=CC=CC=C1OC(F)(F)F NDRQXCRSOHVZSH-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 150000001502 aryl halides Chemical class 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 125000003865 brosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Br)S(*)(=O)=O 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000005660 chlorination reaction Methods 0.000 description 2
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- DQDPZIRMUJBHTI-UHFFFAOYSA-N ethyl 3-(2,6-dichlorophenyl)-5-propan-2-yltriazole-4-carboxylate Chemical compound CCOC(=O)C1=C(C(C)C)N=NN1C1=C(Cl)C=CC=C1Cl DQDPZIRMUJBHTI-UHFFFAOYSA-N 0.000 description 2
- VJPVESOWUMXSCN-UHFFFAOYSA-N ethyl 3-(dimethylaminomethylidene)-4-methyl-2-oxopentanoate Chemical compound CCOC(=O)C(=O)C(C(C)C)=CN(C)C VJPVESOWUMXSCN-UHFFFAOYSA-N 0.000 description 2
- NEEXXQDCFONWJB-UHFFFAOYSA-N ethyl 3-cyclopropyl-2-oxopropanoate Chemical compound CCOC(=O)C(=O)CC1CC1 NEEXXQDCFONWJB-UHFFFAOYSA-N 0.000 description 2
- XQZIRQWYXJKNSV-UHFFFAOYSA-N ethyl 3-cyclopropyl-4-(dimethylamino)-2-oxobut-3-enoate Chemical compound CCOC(=O)C(=O)C(=CN(C)C)C1CC1 XQZIRQWYXJKNSV-UHFFFAOYSA-N 0.000 description 2
- BPTHAGLSIREYQL-UHFFFAOYSA-N ethyl 4-(4-hydroxyazepan-1-yl)benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1N1CCC(O)CCC1 BPTHAGLSIREYQL-UHFFFAOYSA-N 0.000 description 2
- LVUVDRGIMLTUAC-UHFFFAOYSA-N ethyl 4-[4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]azepan-1-yl]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1N1CCC(OCC=2C(=NOC=2C2CC2)C=2C(=CC=CC=2Cl)Cl)CCC1 LVUVDRGIMLTUAC-UHFFFAOYSA-N 0.000 description 2
- XRMJFFUFRCRGBO-UHFFFAOYSA-N ethyl 4-cyclopropyl-2-(2,6-dichlorophenyl)pyrazole-3-carboxylate Chemical compound CCOC(=O)C1=C(C2CC2)C=NN1C1=C(Cl)C=CC=C1Cl XRMJFFUFRCRGBO-UHFFFAOYSA-N 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- KMAKOBLIOCQGJP-UHFFFAOYSA-N indole-3-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=CNC2=C1 KMAKOBLIOCQGJP-UHFFFAOYSA-N 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- KSCRCJTZVKPHIR-UHFFFAOYSA-N methyl 3-cyclopropyl-2-oxopropanoate Chemical compound COC(=O)C(=O)CC1CC1 KSCRCJTZVKPHIR-UHFFFAOYSA-N 0.000 description 2
- RIJWDPRXCXJDPK-UHFFFAOYSA-N methyl 3-cyclopropyl-3-oxopropanoate Chemical compound COC(=O)CC(=O)C1CC1 RIJWDPRXCXJDPK-UHFFFAOYSA-N 0.000 description 2
- AXJMMRAWAKWLBP-UHFFFAOYSA-N methyl 4-(4-hydroxypiperidin-1-yl)-2-phenylbenzoate Chemical compound COC(=O)C1=CC=C(N2CCC(O)CC2)C=C1C1=CC=CC=C1 AXJMMRAWAKWLBP-UHFFFAOYSA-N 0.000 description 2
- TTZKGZNYBSTZIY-UHFFFAOYSA-N methyl 4-[4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]piperidin-1-yl]-2-phenylbenzoate Chemical compound COC(=O)C1=CC=C(N2CCC(CC2)OCC=2C(=NOC=2C2CC2)C=2C(=CC=CC=2Cl)Cl)C=C1C1=CC=CC=C1 TTZKGZNYBSTZIY-UHFFFAOYSA-N 0.000 description 2
- PYRZAWMOFSHAPY-UHFFFAOYSA-N methyl 5-bromo-1-methylindole-2-carboxylate Chemical compound BrC1=CC=C2N(C)C(C(=O)OC)=CC2=C1 PYRZAWMOFSHAPY-UHFFFAOYSA-N 0.000 description 2
- KPFPQTORVKRSRB-UHFFFAOYSA-N methyl 6-(4-hydroxycyclohexen-1-yl)-1-methylindole-3-carboxylate Chemical compound C=1C=C2C(C(=O)OC)=CN(C)C2=CC=1C1=CCC(O)CC1 KPFPQTORVKRSRB-UHFFFAOYSA-N 0.000 description 2
- GXZWHFLTECXMRF-UHFFFAOYSA-N methyl 6-(4-hydroxycyclohexyl)-1-methylindole-3-carboxylate Chemical compound C=1C=C2C(C(=O)OC)=CN(C)C2=CC=1C1CCC(O)CC1 GXZWHFLTECXMRF-UHFFFAOYSA-N 0.000 description 2
- ZZTCHVDDPLWIOK-UHFFFAOYSA-N methyl 6-[4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]piperidin-1-yl]-1-methylindole-3-carboxylate Chemical compound C=1C=C2C(C(=O)OC)=CN(C)C2=CC=1N(CC1)CCC1OCC1=C(C2CC2)ON=C1C1=C(Cl)C=CC=C1Cl ZZTCHVDDPLWIOK-UHFFFAOYSA-N 0.000 description 2
- SWZAJIYUVDGZOZ-UHFFFAOYSA-N methyl 6-[4-[tert-butyl(dimethyl)silyl]oxycyclohexen-1-yl]-1-methylindole-3-carboxylate Chemical compound C=1C=C2C(C(=O)OC)=CN(C)C2=CC=1C1=CCC(O[Si](C)(C)C(C)(C)C)CC1 SWZAJIYUVDGZOZ-UHFFFAOYSA-N 0.000 description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
- KVKFRMCSXWQSNT-UHFFFAOYSA-N n,n'-dimethylethane-1,2-diamine Chemical compound CNCCNC KVKFRMCSXWQSNT-UHFFFAOYSA-N 0.000 description 2
- 102000006255 nuclear receptors Human genes 0.000 description 2
- 108020004017 nuclear receptors Proteins 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
- IPNPIHIZVLFAFP-UHFFFAOYSA-N phosphorus tribromide Chemical compound BrP(Br)Br IPNPIHIZVLFAFP-UHFFFAOYSA-N 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 125000001273 sulfonato group Chemical class [O-]S(*)(=O)=O 0.000 description 2
- PWQLFIKTGRINFF-UHFFFAOYSA-N tert-butyl 4-hydroxypiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(O)CC1 PWQLFIKTGRINFF-UHFFFAOYSA-N 0.000 description 2
- MOOLXPLCBXUFIW-UHFFFAOYSA-N tert-butyl 6-bromo-1-methylindole-3-carboxylate Chemical compound C1=C(Br)C=C2N(C)C=C(C(=O)OC(C)(C)C)C2=C1 MOOLXPLCBXUFIW-UHFFFAOYSA-N 0.000 description 2
- HIHTZBHDBXVHEW-UHFFFAOYSA-N tert-butyl 6-iodo-1-methylindole-3-carboxylate Chemical compound C1=C(I)C=C2N(C)C=C(C(=O)OC(C)(C)C)C2=C1 HIHTZBHDBXVHEW-UHFFFAOYSA-N 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- FQFILJKFZCVHNH-UHFFFAOYSA-N tert-butyl n-[3-[(5-bromo-2-chloropyrimidin-4-yl)amino]propyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCNC1=NC(Cl)=NC=C1Br FQFILJKFZCVHNH-UHFFFAOYSA-N 0.000 description 2
- YORHLCKMVFBFLD-UHFFFAOYSA-N tert-butyl-dimethyl-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cyclohex-3-en-1-yl]oxysilane Chemical compound C1C(O[Si](C)(C)C(C)(C)C)CCC(B2OC(C)(C)C(C)(C)O2)=C1 YORHLCKMVFBFLD-UHFFFAOYSA-N 0.000 description 2
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 2
- 150000008648 triflates Chemical class 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- ONDSBJMLAHVLMI-UHFFFAOYSA-N trimethylsilyldiazomethane Chemical compound C[Si](C)(C)[CH-][N+]#N ONDSBJMLAHVLMI-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- CQNIYLLTIOPFCJ-UHFFFAOYSA-N (2,6-dichlorophenyl)hydrazine;hydron;chloride Chemical compound Cl.NNC1=C(Cl)C=CC=C1Cl CQNIYLLTIOPFCJ-UHFFFAOYSA-N 0.000 description 1
- VTWKXBJHBHYJBI-VURMDHGXSA-N (nz)-n-benzylidenehydroxylamine Chemical compound O\N=C/C1=CC=CC=C1 VTWKXBJHBHYJBI-VURMDHGXSA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- ZXMGHDIOOHOAAE-UHFFFAOYSA-N 1,1,1-trifluoro-n-(trifluoromethylsulfonyl)methanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)NS(=O)(=O)C(F)(F)F ZXMGHDIOOHOAAE-UHFFFAOYSA-N 0.000 description 1
- WMKGGPCROCCUDY-UHFFFAOYSA-N 1,5-diphenylpenta-1,4-dien-3-one Chemical compound C=1C=CC=CC=1C=CC(=O)C=CC1=CC=CC=C1 WMKGGPCROCCUDY-UHFFFAOYSA-N 0.000 description 1
- GIGRWGTZFONRKA-UHFFFAOYSA-N 1-(bromomethyl)-4-methoxybenzene Chemical compound COC1=CC=C(CBr)C=C1 GIGRWGTZFONRKA-UHFFFAOYSA-N 0.000 description 1
- BAUWRHPMUVYFOD-UHFFFAOYSA-N 1-methylpiperidin-4-ol Chemical compound CN1CCC(O)CC1 BAUWRHPMUVYFOD-UHFFFAOYSA-N 0.000 description 1
- HEWZVZIVELJPQZ-UHFFFAOYSA-N 2,2-dimethoxypropane Chemical compound COC(C)(C)OC HEWZVZIVELJPQZ-UHFFFAOYSA-N 0.000 description 1
- JDMFXJULNGEPOI-UHFFFAOYSA-N 2,6-dichloroaniline Chemical compound NC1=C(Cl)C=CC=C1Cl JDMFXJULNGEPOI-UHFFFAOYSA-N 0.000 description 1
- ZEMZPXWZVTUONV-UHFFFAOYSA-N 2-(2-dicyclohexylphosphanylphenyl)-n,n-dimethylaniline Chemical group CN(C)C1=CC=CC=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 ZEMZPXWZVTUONV-UHFFFAOYSA-N 0.000 description 1
- ZWZQVRYITSPCAO-UHFFFAOYSA-N 2-(cyclopropylmethyl)-1,3-dithiane Chemical compound S1CCCSC1CC1CC1 ZWZQVRYITSPCAO-UHFFFAOYSA-N 0.000 description 1
- KRQUFUKTQHISJB-YYADALCUSA-N 2-[(E)-N-[2-(4-chlorophenoxy)propoxy]-C-propylcarbonimidoyl]-3-hydroxy-5-(thian-3-yl)cyclohex-2-en-1-one Chemical compound CCC\C(=N/OCC(C)OC1=CC=C(Cl)C=C1)C1=C(O)CC(CC1=O)C1CCCSC1 KRQUFUKTQHISJB-YYADALCUSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- RRKPMLZRLKTDQV-UHFFFAOYSA-N 2-bromo-4-fluorobenzoic acid Chemical compound OC(=O)C1=CC=C(F)C=C1Br RRKPMLZRLKTDQV-UHFFFAOYSA-N 0.000 description 1
- LSVLMFBVUQQWOQ-UHFFFAOYSA-N 4-(4-hydroxycyclohexyl)phenol Chemical compound C1CC(O)CCC1C1=CC=C(O)C=C1 LSVLMFBVUQQWOQ-UHFFFAOYSA-N 0.000 description 1
- ZVJOZHCWQAOEIU-UHFFFAOYSA-N 4-(4-hydroxypiperidin-1-yl)naphthalene-1-carboxylic acid Chemical compound C1CC(O)CCN1C1=CC=C(C(O)=O)C2=CC=CC=C12 ZVJOZHCWQAOEIU-UHFFFAOYSA-N 0.000 description 1
- ASUOJHVBKLGTTQ-UHFFFAOYSA-N 4-(azepan-4-yloxymethyl)-3-(2,6-dichlorophenyl)-5-ethyl-1,2-oxazole Chemical compound CCC=1ON=C(C=2C(=CC=CC=2Cl)Cl)C=1COC1CCCNCC1 ASUOJHVBKLGTTQ-UHFFFAOYSA-N 0.000 description 1
- SNTVMCRGGGYQKW-UHFFFAOYSA-N 4-(azepan-4-yloxymethyl)-5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazole;hydrochloride Chemical compound Cl.ClC1=CC=CC(Cl)=C1C1=NOC(C2CC2)=C1COC1CCNCCC1 SNTVMCRGGGYQKW-UHFFFAOYSA-N 0.000 description 1
- RIQGCEUCEOXTEW-UHFFFAOYSA-N 4-(azepan-4-yloxymethyl)-5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazole Chemical compound FC(F)(F)OC1=CC=CC=C1C1=NOC(C2CC2)=C1COC1CCNCCC1 RIQGCEUCEOXTEW-UHFFFAOYSA-N 0.000 description 1
- DEZDVAAAZZONAM-UHFFFAOYSA-N 4-(bromomethyl)-5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazole Chemical compound FC(F)(F)OC1=CC=CC=C1C1=NOC(C2CC2)=C1CBr DEZDVAAAZZONAM-UHFFFAOYSA-N 0.000 description 1
- KHTDSBQSIFFNSJ-UHFFFAOYSA-N 4-[4-[[3-(2,6-dichlorophenyl)-5-(trifluoromethyl)triazol-4-yl]methoxy]piperidin-1-yl]benzoic acid Chemical compound ClC1=C(C(=CC=C1)Cl)N1N=NC(=C1COC1CCN(CC1)C1=CC=C(C(=O)O)C=C1)C(F)(F)F KHTDSBQSIFFNSJ-UHFFFAOYSA-N 0.000 description 1
- KLKSMSZZLBFWCT-UHFFFAOYSA-N 4-[4-[[5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl]methoxy]cyclohexyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1CCC(OCC=2C(=NOC=2C2CC2)C=2C(=CC=CC=2)OC(F)(F)F)CC1 KLKSMSZZLBFWCT-UHFFFAOYSA-N 0.000 description 1
- YVZHKWHJDHZPIL-UHFFFAOYSA-N 4-[4-[[5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl]methoxy]cyclohexyl]phenol Chemical compound C1=CC(O)=CC=C1C1CCC(OCC=2C(=NOC=2C2CC2)C=2C(=CC=CC=2)OC(F)(F)F)CC1 YVZHKWHJDHZPIL-UHFFFAOYSA-N 0.000 description 1
- JAXYNSFCMQQFFJ-UHFFFAOYSA-N 4-[[2-(2,6-dichlorophenyl)-4-propan-2-ylpyrazol-3-yl]methoxy]azepane Chemical compound CC(C)C=1C=NN(C=2C(=CC=CC=2Cl)Cl)C=1COC1CCCNCC1 JAXYNSFCMQQFFJ-UHFFFAOYSA-N 0.000 description 1
- WHWHLSCLHDIBJJ-UHFFFAOYSA-N 4-[[3-(2,6-dichlorophenyl)-5-propan-2-yltriazol-4-yl]methoxy]azepane Chemical compound CC(C)C=1N=NN(C=2C(=CC=CC=2Cl)Cl)C=1COC1CCCNCC1 WHWHLSCLHDIBJJ-UHFFFAOYSA-N 0.000 description 1
- HXKBGMNGSYGPRB-UHFFFAOYSA-N 4-[tert-butyl(dimethyl)silyl]oxycyclohexan-1-one Chemical compound CC(C)(C)[Si](C)(C)OC1CCC(=O)CC1 HXKBGMNGSYGPRB-UHFFFAOYSA-N 0.000 description 1
- GENORMKKUHHVGE-UHFFFAOYSA-N 4-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazole Chemical compound C1(CC1)C=1C(=NOC=1)C1=C(C=CC=C1Cl)Cl GENORMKKUHHVGE-UHFFFAOYSA-N 0.000 description 1
- MGRMLERTDJOCBT-UHFFFAOYSA-N 4-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazole Chemical compound C1(CC1)C=1C(=NOC=1)C1=C(C=CC=C1)OC(F)(F)F MGRMLERTDJOCBT-UHFFFAOYSA-N 0.000 description 1
- 239000001142 4-methyl-2-oxopentanoic acid Substances 0.000 description 1
- KLWGJPJVWADJLY-UHFFFAOYSA-N 5-(bromomethyl)-1-(2,6-dichlorophenyl)-4-(trifluoromethyl)triazole Chemical compound BrCC1=C(C(F)(F)F)N=NN1C1=C(Cl)C=CC=C1Cl KLWGJPJVWADJLY-UHFFFAOYSA-N 0.000 description 1
- OQLNQGGMNNSYOV-UHFFFAOYSA-N 5-(bromomethyl)-4-cyclopropyl-1-(2,6-dichlorophenyl)pyrazole Chemical compound ClC1=CC=CC(Cl)=C1N1C(CBr)=C(C2CC2)C=N1 OQLNQGGMNNSYOV-UHFFFAOYSA-N 0.000 description 1
- VMJDXPHCCSCUEP-UHFFFAOYSA-N 5-(bromomethyl)-4-cyclopropyl-1-(2,6-dichlorophenyl)triazole Chemical compound ClC1=CC=CC(Cl)=C1N1C(CBr)=C(C2CC2)N=N1 VMJDXPHCCSCUEP-UHFFFAOYSA-N 0.000 description 1
- XPZCNCBJPJHRQA-UHFFFAOYSA-N 5-cyclopropyl-4-[[4-[4-[(4-methoxyphenyl)methoxy]phenyl]cyclohexyl]oxymethyl]-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazole Chemical compound C1=CC(OC)=CC=C1COC1=CC=C(C2CCC(CC2)OCC=2C(=NOC=2C2CC2)C=2C(=CC=CC=2)OC(F)(F)F)C=C1 XPZCNCBJPJHRQA-UHFFFAOYSA-N 0.000 description 1
- LAWNXRYHSVZIGR-UHFFFAOYSA-N 6-(4-hydroxypiperidin-1-yl)-1-methylindole-3-carboxylic acid Chemical compound OC1CCN(CC1)C1=CC=C2C(=CN(C2=C1)C)C(=O)O LAWNXRYHSVZIGR-UHFFFAOYSA-N 0.000 description 1
- ANGDXDPWIYHNID-UHFFFAOYSA-N 6-[4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]azepan-1-yl]-1,2-benzothiazole-3-carboxylic acid Chemical compound C=1C=C2C(C(=O)O)=NSC2=CC=1N(CC1)CCCC1OCC1=C(C2CC2)ON=C1C1=C(Cl)C=CC=C1Cl ANGDXDPWIYHNID-UHFFFAOYSA-N 0.000 description 1
- FWQJCLJQWQXNTD-UHFFFAOYSA-N 6-bromo-1,2-benzothiazole-3-carboxylic acid Chemical compound BrC1=CC=C2C(C(=O)O)=NSC2=C1 FWQJCLJQWQXNTD-UHFFFAOYSA-N 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 239000004135 Bone phosphate Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- XWFHYVFJWWYLTE-UHFFFAOYSA-N C1(CC1)C1=C(C(=NO1)C1=C(C=CC=C1)OC(F)(F)F)COC1CCN(CCC1)C1=CC=C2C(=CN(C2=C1)C)C(=O)O Chemical compound C1(CC1)C1=C(C(=NO1)C1=C(C=CC=C1)OC(F)(F)F)COC1CCN(CCC1)C1=CC=C2C(=CN(C2=C1)C)C(=O)O XWFHYVFJWWYLTE-UHFFFAOYSA-N 0.000 description 1
- ICNZTSZLONHVQX-UHFFFAOYSA-N C1(CC1)C1=C(C(=NO1)C1=C(C=CC=C1)OC(F)(F)F)COC1CCN(CCC1)C=1C=CC2=C(SC=C2C(=O)O)C=1 Chemical compound C1(CC1)C1=C(C(=NO1)C1=C(C=CC=C1)OC(F)(F)F)COC1CCN(CCC1)C=1C=CC2=C(SC=C2C(=O)O)C=1 ICNZTSZLONHVQX-UHFFFAOYSA-N 0.000 description 1
- RKSXOUYYKNIWSI-UHFFFAOYSA-N C1(CC1)C1=C(C(=NO1)C1=C(C=CC=C1Cl)Cl)COC1CCN(CCC1)C1=CC=C2C(=NN(C2=C1)C)C(=O)O Chemical compound C1(CC1)C1=C(C(=NO1)C1=C(C=CC=C1Cl)Cl)COC1CCN(CCC1)C1=CC=C2C(=NN(C2=C1)C)C(=O)O RKSXOUYYKNIWSI-UHFFFAOYSA-N 0.000 description 1
- ZUBLEHKQIQAUJB-UHFFFAOYSA-N C1(CC1)C1=C(C(=NO1)C1=C(C=CC=C1Cl)Cl)COC1CCN(CCC1)C=1C=CC2=C(SC(=C2)C(=O)O)C=1 Chemical compound C1(CC1)C1=C(C(=NO1)C1=C(C=CC=C1Cl)Cl)COC1CCN(CCC1)C=1C=CC2=C(SC(=C2)C(=O)O)C=1 ZUBLEHKQIQAUJB-UHFFFAOYSA-N 0.000 description 1
- MNFGUAUKRMYJJP-UHFFFAOYSA-N CC(C)c1cnn(c1COC1CCCN(CC1)c1ccc(cc1)C(O)=O)-c1c(Cl)cccc1Cl Chemical compound CC(C)c1cnn(c1COC1CCCN(CC1)c1ccc(cc1)C(O)=O)-c1c(Cl)cccc1Cl MNFGUAUKRMYJJP-UHFFFAOYSA-N 0.000 description 1
- XIGPBHWMRULRGL-UHFFFAOYSA-N CC(C)c1cnn(c1COC1CCN(CC1)c1ccc(cc1)C(O)=O)-c1c(Cl)cccc1Cl Chemical compound CC(C)c1cnn(c1COC1CCN(CC1)c1ccc(cc1)C(O)=O)-c1c(Cl)cccc1Cl XIGPBHWMRULRGL-UHFFFAOYSA-N 0.000 description 1
- CFBTZSZQALFJQC-UHFFFAOYSA-N CC(C)c1nnn(c1COC1CCCN(CC1)c1ccc(cc1)C(O)=O)-c1c(Cl)cccc1Cl Chemical compound CC(C)c1nnn(c1COC1CCCN(CC1)c1ccc(cc1)C(O)=O)-c1c(Cl)cccc1Cl CFBTZSZQALFJQC-UHFFFAOYSA-N 0.000 description 1
- ZOSQWDBWIXIDAA-UHFFFAOYSA-N CC(C)c1nnn(c1COC1CCN(CC1)c1ccc(cc1)C(O)=O)-c1c(Cl)cccc1Cl Chemical compound CC(C)c1nnn(c1COC1CCN(CC1)c1ccc(cc1)C(O)=O)-c1c(Cl)cccc1Cl ZOSQWDBWIXIDAA-UHFFFAOYSA-N 0.000 description 1
- SALVNJCTYZSNMT-UHFFFAOYSA-N CC1=C2C(=NN(C2=CC(=C1)Br)C)C(=O)O Chemical compound CC1=C2C(=NN(C2=CC(=C1)Br)C)C(=O)O SALVNJCTYZSNMT-UHFFFAOYSA-N 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010008635 Cholestasis Diseases 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- HIDSJXGWMMBMMG-UHFFFAOYSA-N Cl.ClN(NC1=CC=CC=C1)Cl Chemical compound Cl.ClN(NC1=CC=CC=C1)Cl HIDSJXGWMMBMMG-UHFFFAOYSA-N 0.000 description 1
- WALYFIVJXKZKDN-UHFFFAOYSA-N Cn1nc(C(O)=O)c2ccc(cc12)N1CCC(CC1)OCc1c(onc1-c1c(Cl)cccc1Cl)C1CC1 Chemical compound Cn1nc(C(O)=O)c2ccc(cc12)N1CCC(CC1)OCc1c(onc1-c1c(Cl)cccc1Cl)C1CC1 WALYFIVJXKZKDN-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101000602926 Homo sapiens Nuclear receptor coactivator 1 Proteins 0.000 description 1
- SHBUUTHKGIVMJT-UHFFFAOYSA-N Hydroxystearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OO SHBUUTHKGIVMJT-UHFFFAOYSA-N 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 102000000853 LDL receptors Human genes 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229910015853 MSO4 Inorganic materials 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 1
- XSUXDJHVNPNNFJ-UHFFFAOYSA-N OBOC=C Chemical compound OBOC=C XSUXDJHVNPNNFJ-UHFFFAOYSA-N 0.000 description 1
- DSMUYEVKEDYDSH-UHFFFAOYSA-N OC(=O)c1cc2cc(ccc2s1)N1CCC(CC1)OCc1c(onc1-c1c(Cl)cccc1Cl)C1CC1 Chemical compound OC(=O)c1cc2cc(ccc2s1)N1CCC(CC1)OCc1c(onc1-c1c(Cl)cccc1Cl)C1CC1 DSMUYEVKEDYDSH-UHFFFAOYSA-N 0.000 description 1
- CVWNZIDSFJWTTO-UHFFFAOYSA-N OC(=O)c1cc2cc(ccc2s1)N1CCCC(CC1)OCc1c(onc1-c1c(Cl)cccc1Cl)C1CC1 Chemical compound OC(=O)c1cc2cc(ccc2s1)N1CCCC(CC1)OCc1c(onc1-c1c(Cl)cccc1Cl)C1CC1 CVWNZIDSFJWTTO-UHFFFAOYSA-N 0.000 description 1
- HJACANJOEPFVEX-UHFFFAOYSA-N OC(=O)c1ccc(cc1)N1CCC(CC1)OCc1c(cnn1-c1c(Cl)cccc1Cl)C1CC1 Chemical compound OC(=O)c1ccc(cc1)N1CCC(CC1)OCc1c(cnn1-c1c(Cl)cccc1Cl)C1CC1 HJACANJOEPFVEX-UHFFFAOYSA-N 0.000 description 1
- CJENKCXNQPZQGT-UHFFFAOYSA-N OC(=O)c1ccc(cc1)N1CCC(CC1)OCc1c(nnn1-c1c(Cl)cccc1Cl)C1CC1 Chemical compound OC(=O)c1ccc(cc1)N1CCC(CC1)OCc1c(nnn1-c1c(Cl)cccc1Cl)C1CC1 CJENKCXNQPZQGT-UHFFFAOYSA-N 0.000 description 1
- FACBYVFKJQDJEN-UHFFFAOYSA-N OC(=O)c1ccc(cc1)N1CCCC(CC1)OCc1c(onc1-c1ccccc1OC(F)(F)F)C1CC1 Chemical compound OC(=O)c1ccc(cc1)N1CCCC(CC1)OCc1c(onc1-c1ccccc1OC(F)(F)F)C1CC1 FACBYVFKJQDJEN-UHFFFAOYSA-N 0.000 description 1
- PYNFIGBAHXLSNV-UHFFFAOYSA-N OC(=O)c1cccc(c1)N1CCCC(CC1)OCc1c(onc1-c1c(Cl)cccc1Cl)C1CC1 Chemical compound OC(=O)c1cccc(c1)N1CCCC(CC1)OCc1c(onc1-c1c(Cl)cccc1Cl)C1CC1 PYNFIGBAHXLSNV-UHFFFAOYSA-N 0.000 description 1
- ZNBNBFLQDHMGTA-UHFFFAOYSA-N OC(=O)c1nsc2cc(ccc12)N1CCC(CC1)OCc1c(onc1-c1c(Cl)cccc1Cl)C1CC1 Chemical compound OC(=O)c1nsc2cc(ccc12)N1CCC(CC1)OCc1c(onc1-c1c(Cl)cccc1Cl)C1CC1 ZNBNBFLQDHMGTA-UHFFFAOYSA-N 0.000 description 1
- CGFNPWLEVAXVPT-UHFFFAOYSA-N ON.C(C1=CC=CC=C1)=O Chemical class ON.C(C1=CC=CC=C1)=O CGFNPWLEVAXVPT-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 108010069201 VLDL Cholesterol Proteins 0.000 description 1
- 235000021068 Western diet Nutrition 0.000 description 1
- IJVUIOCXNVEGKH-UHFFFAOYSA-N [3-(2,6-dichlorophenyl)-5-propan-2-yltriazol-4-yl]methanol Chemical compound OCC1=C(C(C)C)N=NN1C1=C(Cl)C=CC=C1Cl IJVUIOCXNVEGKH-UHFFFAOYSA-N 0.000 description 1
- MOJGKMCKEOASCT-UHFFFAOYSA-N [4-cyclopropyl-2-(2,6-dichlorophenyl)pyrazol-3-yl]methanol Chemical compound OCC1=C(C2CC2)C=NN1C1=C(Cl)C=CC=C1Cl MOJGKMCKEOASCT-UHFFFAOYSA-N 0.000 description 1
- KZJNNOCWILZPAY-UHFFFAOYSA-N [5-cyclopropyl-3-(2,6-dichlorophenyl)triazol-4-yl]methanol Chemical compound OCC1=C(C2CC2)N=NN1C1=C(Cl)C=CC=C1Cl KZJNNOCWILZPAY-UHFFFAOYSA-N 0.000 description 1
- VUTSITSGGYCKFP-UHFFFAOYSA-J [C+4].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O Chemical compound [C+4].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O VUTSITSGGYCKFP-UHFFFAOYSA-J 0.000 description 1
- ZPHOLCSIRUXFAD-UHFFFAOYSA-N [[2-(trifluoromethoxy)phenyl]methylideneamino] hypochlorite Chemical compound FC(F)(F)OC1=CC=CC=C1C=NOCl ZPHOLCSIRUXFAD-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 150000001499 aryl bromides Chemical class 0.000 description 1
- WFTRLIZPJMFJER-UHFFFAOYSA-N azepan-1-ium-4-one;chloride Chemical compound Cl.O=C1CCCNCC1 WFTRLIZPJMFJER-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- AEILLAXRDHDKDY-UHFFFAOYSA-N bromomethylcyclopropane Chemical compound BrCC1CC1 AEILLAXRDHDKDY-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 230000036996 cardiovascular health Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 150000003983 crown ethers Chemical class 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000002243 cyclohexanonyl group Chemical class *C1(*)C(=O)C(*)(*)C(*)(*)C(*)(*)C1(*)* 0.000 description 1
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexyloxide Natural products O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- MDHVAGISVVVEJD-UHFFFAOYSA-N diazonio-[2-(trifluoromethoxy)phenyl]azanide Chemical compound FC(F)(F)OC1=CC=CC=C1N=[N+]=[N-] MDHVAGISVVVEJD-UHFFFAOYSA-N 0.000 description 1
- WMKGGPCROCCUDY-PHEQNACWSA-N dibenzylideneacetone Chemical compound C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 WMKGGPCROCCUDY-PHEQNACWSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- IEJIGPNLZYLLBP-UHFFFAOYSA-N dimethyl carbonate Chemical compound COC(=O)OC IEJIGPNLZYLLBP-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- VDDXQSUSMHZCLS-UHFFFAOYSA-N ethenyl trifluoromethanesulfonate Chemical compound FC(F)(F)S(=O)(=O)OC=C VDDXQSUSMHZCLS-UHFFFAOYSA-N 0.000 description 1
- ANEDZEVDORCLPM-UHFFFAOYSA-N ethyl 1,3-dithiane-2-carboxylate Chemical compound CCOC(=O)C1SCCCS1 ANEDZEVDORCLPM-UHFFFAOYSA-N 0.000 description 1
- RDUGFSAQGVRWPZ-UHFFFAOYSA-N ethyl 2-(cyclopropylmethyl)-1,3-dithiane-2-carboxylate Chemical compound C1CC1CC1(C(=O)OCC)SCCCS1 RDUGFSAQGVRWPZ-UHFFFAOYSA-N 0.000 description 1
- FCZCIXQGZOUIDN-UHFFFAOYSA-N ethyl 2-diethoxyphosphinothioyloxyacetate Chemical compound CCOC(=O)COP(=S)(OCC)OCC FCZCIXQGZOUIDN-UHFFFAOYSA-N 0.000 description 1
- HFBUFVYPHLRXGE-UHFFFAOYSA-N ethyl 3-(2,6-dichlorophenyl)-5-(trifluoromethyl)triazole-4-carboxylate Chemical compound CCOC(=O)C1=C(C(F)(F)F)N=NN1C1=C(Cl)C=CC=C1Cl HFBUFVYPHLRXGE-UHFFFAOYSA-N 0.000 description 1
- UQULYDYHMOUQQK-UHFFFAOYSA-N ethyl 4-(4-hydroxypiperidin-1-yl)benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1N1CCC(O)CC1 UQULYDYHMOUQQK-UHFFFAOYSA-N 0.000 description 1
- RLEUBLNVHZTFOH-UHFFFAOYSA-N ethyl 5-bromo-1-methylindole-2-carboxylate Chemical compound BrC1=CC=C2N(C)C(C(=O)OCC)=CC2=C1 RLEUBLNVHZTFOH-UHFFFAOYSA-N 0.000 description 1
- LWRLKENDQISGEU-UHFFFAOYSA-N ethyl 5-bromo-1h-indole-2-carboxylate Chemical compound BrC1=CC=C2NC(C(=O)OCC)=CC2=C1 LWRLKENDQISGEU-UHFFFAOYSA-N 0.000 description 1
- LGZZUZGQMGIGOF-UHFFFAOYSA-N ethyl 6-(4-hydroxypiperidin-1-yl)-1-benzothiophene-3-carboxylate Chemical compound C=1C=C2C(C(=O)OCC)=CSC2=CC=1N1CCC(O)CC1 LGZZUZGQMGIGOF-UHFFFAOYSA-N 0.000 description 1
- POLGDYGGGGODRD-UHFFFAOYSA-N ethyl 6-bromo-1-benzothiophene-3-carboxylate Chemical compound BrC1=CC=C2C(C(=O)OCC)=CSC2=C1 POLGDYGGGGODRD-UHFFFAOYSA-N 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 102000053772 human NCOA1 Human genes 0.000 description 1
- 229940072106 hydroxystearate Drugs 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 150000002496 iodine Chemical class 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Substances CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- IGNYATYBADTSRK-UHFFFAOYSA-N methyl 2-(2,6-dichlorophenyl)-4-propan-2-ylpyrazole-3-carboxylate Chemical compound COC(=O)C1=C(C(C)C)C=NN1C1=C(Cl)C=CC=C1Cl IGNYATYBADTSRK-UHFFFAOYSA-N 0.000 description 1
- PSNASVSHMCSVCF-UHFFFAOYSA-N methyl 4-(4-hydroxypiperidin-1-yl)-2-methylbenzoate Chemical compound C1=C(C)C(C(=O)OC)=CC=C1N1CCC(O)CC1 PSNASVSHMCSVCF-UHFFFAOYSA-N 0.000 description 1
- PVTVSSZUBBMZEP-UHFFFAOYSA-N methyl 4-(4-hydroxypiperidin-1-yl)-3-methylbenzoate Chemical compound CC1=CC(C(=O)OC)=CC=C1N1CCC(O)CC1 PVTVSSZUBBMZEP-UHFFFAOYSA-N 0.000 description 1
- XXLDDXIGGIGUMC-UHFFFAOYSA-N methyl 4-(4-hydroxypiperidin-1-yl)benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1N1CCC(O)CC1 XXLDDXIGGIGUMC-UHFFFAOYSA-N 0.000 description 1
- CYEXEOXALMJXDI-UHFFFAOYSA-N methyl 4-bromo-2-methylbenzoate Chemical compound COC(=O)C1=CC=C(Br)C=C1C CYEXEOXALMJXDI-UHFFFAOYSA-N 0.000 description 1
- GTZTYNPAPQKIIR-UHFFFAOYSA-N methyl 4-bromo-3-methylbenzoate Chemical compound COC(=O)C1=CC=C(Br)C(C)=C1 GTZTYNPAPQKIIR-UHFFFAOYSA-N 0.000 description 1
- ZQFCTCYDRQFPBU-UHFFFAOYSA-N methyl 4-fluoro-2-methylbenzoate Chemical compound COC(=O)C1=CC=C(F)C=C1C ZQFCTCYDRQFPBU-UHFFFAOYSA-N 0.000 description 1
- BGKRQQWFGKBQFV-UHFFFAOYSA-N methyl 4-fluoronaphthalene-1-carboxylate Chemical compound C1=CC=C2C(C(=O)OC)=CC=C(F)C2=C1 BGKRQQWFGKBQFV-UHFFFAOYSA-N 0.000 description 1
- LFVDEVQENPHSSD-UHFFFAOYSA-N methyl 4-methyl-2-oxopentanoate Chemical compound COC(=O)C(=O)CC(C)C LFVDEVQENPHSSD-UHFFFAOYSA-N 0.000 description 1
- UYFFMVDJHCONSM-UHFFFAOYSA-N methyl 5-cyclopropyl-3-(2,6-dichlorophenyl)triazole-4-carboxylate Chemical compound COC(=O)C1=C(C2CC2)N=NN1C1=C(Cl)C=CC=C1Cl UYFFMVDJHCONSM-UHFFFAOYSA-N 0.000 description 1
- INMVEWNAYCVPAI-UHFFFAOYSA-N methyl 5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazole-4-carboxylate Chemical compound COC(=O)C1=C(C2CC2)ON=C1C1=CC=CC=C1OC(F)(F)F INMVEWNAYCVPAI-UHFFFAOYSA-N 0.000 description 1
- UNRKATDIBLYQMJ-UHFFFAOYSA-N methyl 6-(4-hydroxypiperidin-1-yl)-1-methylindole-3-carboxylate Chemical compound C=1C=C2C(C(=O)OC)=CN(C)C2=CC=1N1CCC(O)CC1 UNRKATDIBLYQMJ-UHFFFAOYSA-N 0.000 description 1
- AXMOFWOWVOWQGA-UHFFFAOYSA-N methyl 6-[4-[[3-(2,6-dichlorophenyl)-5-propan-2-yl-1,2-oxazol-4-yl]methoxy]piperidin-1-yl]-1-methylindole-3-carboxylate Chemical compound C=1C=C2C(C(=O)OC)=CN(C)C2=CC=1N(CC1)CCC1OCC1=C(C(C)C)ON=C1C1=C(Cl)C=CC=C1Cl AXMOFWOWVOWQGA-UHFFFAOYSA-N 0.000 description 1
- SSWKGOFXGAQDQI-UHFFFAOYSA-N methyl 6-[4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]azepan-1-yl]-1-methylindole-3-carboxylate Chemical compound C=1C=C2C(C(=O)OC)=CN(C)C2=CC=1N(CC1)CCCC1OCC1=C(C2CC2)ON=C1C1=C(Cl)C=CC=C1Cl SSWKGOFXGAQDQI-UHFFFAOYSA-N 0.000 description 1
- SYHZKIFISNPPNF-UHFFFAOYSA-N methyl 6-bromo-1,2-benzothiazole-3-carboxylate Chemical compound BrC1=CC=C2C(C(=O)OC)=NSC2=C1 SYHZKIFISNPPNF-UHFFFAOYSA-N 0.000 description 1
- SJICLOHNXORMBV-UHFFFAOYSA-N methyl 6-bromo-1-methylindazole-3-carboxylate Chemical compound BrC1=CC=C2C(C(=O)OC)=NN(C)C2=C1 SJICLOHNXORMBV-UHFFFAOYSA-N 0.000 description 1
- RCDWEKOOOHATJC-UHFFFAOYSA-N methyl 6-bromo-1-methylindole-2-carboxylate Chemical compound C1=C(Br)C=C2N(C)C(C(=O)OC)=CC2=C1 RCDWEKOOOHATJC-UHFFFAOYSA-N 0.000 description 1
- FIPMZRPZSZXFGK-UHFFFAOYSA-N methyl 6-bromo-1h-indazole-3-carboxylate Chemical compound BrC1=CC=C2C(C(=O)OC)=NNC2=C1 FIPMZRPZSZXFGK-UHFFFAOYSA-N 0.000 description 1
- RMEDXVIWDFLGES-UHFFFAOYSA-N methyl 6-chloropyridine-3-carboxylate Chemical compound COC(=O)C1=CC=C(Cl)N=C1 RMEDXVIWDFLGES-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- PYLWMHQQBFSUBP-UHFFFAOYSA-N monofluorobenzene Chemical compound FC1=CC=CC=C1 PYLWMHQQBFSUBP-UHFFFAOYSA-N 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- DAZXVJBJRMWXJP-UHFFFAOYSA-N n,n-dimethylethylamine Chemical compound CCN(C)C DAZXVJBJRMWXJP-UHFFFAOYSA-N 0.000 description 1
- ZMULZVILNURIQY-UHFFFAOYSA-N n-[[2-(trifluoromethoxy)phenyl]methylidene]hydroxylamine Chemical compound ON=CC1=CC=CC=C1OC(F)(F)F ZMULZVILNURIQY-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 238000007339 nucleophilic aromatic substitution reaction Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000011049 pearl Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- CUQOHAYJWVTKDE-UHFFFAOYSA-N potassium;butan-1-olate Chemical group [K+].CCCC[O-] CUQOHAYJWVTKDE-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical class [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- XVGGTJFCFVTPHU-UHFFFAOYSA-N tert-butyl 4-[[2-(2,6-dichlorophenyl)-4-propan-2-ylpyrazol-3-yl]methoxy]azepane-1-carboxylate Chemical compound CC(C)C=1C=NN(C=2C(=CC=CC=2Cl)Cl)C=1COC1CCCN(C(=O)OC(C)(C)C)CC1 XVGGTJFCFVTPHU-UHFFFAOYSA-N 0.000 description 1
- USTZPTCJKVNIIV-UHFFFAOYSA-N tert-butyl 4-[[3-(2,6-dichlorophenyl)-5-propan-2-yltriazol-4-yl]methoxy]azepane-1-carboxylate Chemical compound CC(C)C=1N=NN(C=2C(=CC=CC=2Cl)Cl)C=1COC1CCCN(C(=O)OC(C)(C)C)CC1 USTZPTCJKVNIIV-UHFFFAOYSA-N 0.000 description 1
- ZKHBDABIHODVFL-UHFFFAOYSA-N tert-butyl 4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OCC1=C(C2CC2)ON=C1C1=C(Cl)C=CC=C1Cl ZKHBDABIHODVFL-UHFFFAOYSA-N 0.000 description 1
- RMVQHDPUYWWOTA-UHFFFAOYSA-N tert-butyl 6-[4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]piperidin-1-yl]-1-methylindole-3-carboxylate Chemical compound C1=C2N(C)C=C(C(=O)OC(C)(C)C)C2=CC=C1N(CC1)CCC1OCC1=C(C2CC2)ON=C1C1=C(Cl)C=CC=C1Cl RMVQHDPUYWWOTA-UHFFFAOYSA-N 0.000 description 1
- XBXCNNQPRYLIDE-UHFFFAOYSA-N tert-butylcarbamic acid Chemical compound CC(C)(C)NC(O)=O XBXCNNQPRYLIDE-UHFFFAOYSA-N 0.000 description 1
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 1
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94997407P | 2007-07-16 | 2007-07-16 | |
| US949974P | 2007-07-16 | ||
| PCT/US2008/069719 WO2009012125A1 (en) | 2007-07-16 | 2008-07-11 | Compounds and methods for modulating fxr |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2376176T3 true ES2376176T3 (es) | 2012-03-09 |
Family
ID=39855171
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES08781651T Active ES2376176T3 (es) | 2007-07-16 | 2008-07-11 | Compuestos y procedimientos para modular fxr. |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US8153624B2 (enExample) |
| EP (1) | EP2178851B1 (enExample) |
| JP (1) | JP5373788B2 (enExample) |
| KR (1) | KR101157334B1 (enExample) |
| CN (1) | CN101743232B (enExample) |
| AR (1) | AR067540A1 (enExample) |
| AT (1) | ATE539065T1 (enExample) |
| AU (1) | AU2008276236B2 (enExample) |
| BR (1) | BRPI0814571A2 (enExample) |
| CA (1) | CA2693406C (enExample) |
| CL (1) | CL2008002051A1 (enExample) |
| CO (1) | CO6270212A2 (enExample) |
| CY (1) | CY1112298T1 (enExample) |
| DK (1) | DK2178851T3 (enExample) |
| DO (1) | DOP2010000018A (enExample) |
| EA (1) | EA016475B1 (enExample) |
| EC (1) | ECSP109879A (enExample) |
| ES (1) | ES2376176T3 (enExample) |
| HR (1) | HRP20120048T1 (enExample) |
| IL (1) | IL202234A0 (enExample) |
| MA (1) | MA31683B1 (enExample) |
| MX (1) | MX2010000502A (enExample) |
| PE (1) | PE20090809A1 (enExample) |
| PL (1) | PL2178851T3 (enExample) |
| PT (1) | PT2178851E (enExample) |
| RS (1) | RS52216B (enExample) |
| SI (1) | SI2178851T1 (enExample) |
| SV (1) | SV2010003458A (enExample) |
| TN (1) | TN2010000028A1 (enExample) |
| TW (1) | TW200906823A (enExample) |
| WO (1) | WO2009012125A1 (enExample) |
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2289883A1 (en) * | 2009-08-19 | 2011-03-02 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012087520A1 (en) * | 2010-12-20 | 2012-06-28 | Irm Llc | Compositions and methods for modulating farnesoid x receptors |
| CU24152B1 (es) * | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
| EP2655369A1 (en) * | 2010-12-20 | 2013-10-30 | Irm Llc | Compositions and methods for modulating farnesoid x receptors |
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| WO2013037482A1 (en) | 2011-09-15 | 2013-03-21 | Phenex Pharmaceuticals Ag | Farnesoid x receptor agonists for cancer treatment and prevention |
| US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| CA2905242C (en) | 2013-03-15 | 2016-11-29 | Pfizer Inc. | Indole compounds that activate ampk |
| ES2846183T3 (es) | 2013-09-11 | 2021-07-28 | Inst Nat Sante Rech Med | Métodos y composiciones farmacéuticas para el tratamiento de la infección por el virus de la hepatitis B |
| BR112016009630B1 (pt) * | 2013-11-05 | 2021-02-09 | Novartis Ag | receptores de farnesoide x, seus usos, combinação e composição farmacêutica |
| CN104045635A (zh) * | 2014-06-23 | 2014-09-17 | 华东理工大学 | 3,4,5-三取代异恶唑类化合物及其用途 |
| EP3006939A1 (en) | 2014-10-06 | 2016-04-13 | Gilead Sciences, Inc. | Histidine-rich Glycoprotein as a marker for hepatic Farnesoid X receptor activation |
| US10208081B2 (en) | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
| EP3034501A1 (en) | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Hydroxy containing FXR (NR1H4) modulating compounds |
| EP3034499A1 (en) * | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Novel FXR (NR1H4) modulating compounds |
| AU2016215179B2 (en) | 2015-02-06 | 2021-02-25 | Intercept Pharmaceuticals, Inc. | Pharmaceutical compositions for combination therapy |
| TWI698430B (zh) | 2015-02-13 | 2020-07-11 | 南北兄弟藥業投資有限公司 | 三環化合物及其在藥物中的應用 |
| NZ735126A (en) | 2015-03-31 | 2022-10-28 | Enanta Pharm Inc | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof |
| PE20180034A1 (es) | 2015-04-07 | 2018-01-09 | Intercept Pharmaceuticals Inc | Composiciones farmaceuticas para terapias combinadas |
| CN106946867B (zh) * | 2016-01-06 | 2019-11-12 | 广州市恒诺康医药科技有限公司 | Fxr受体调节剂及其制备方法和用途 |
| CN107021958A (zh) * | 2016-02-01 | 2017-08-08 | 山东轩竹医药科技有限公司 | Fxr受体激动剂 |
| SG11201808607SA (en) | 2016-03-28 | 2018-11-29 | Intercept Pharmaceuticals Inc | Medicine obtained by combining fxr agonist and arb |
| WO2017189652A1 (en) | 2016-04-26 | 2017-11-02 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| WO2017189663A1 (en) | 2016-04-26 | 2017-11-02 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| WO2017189651A1 (en) * | 2016-04-26 | 2017-11-02 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| WO2017201155A1 (en) | 2016-05-18 | 2017-11-23 | Enanta Pharmaceuticals, Inc. | lSOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF |
| WO2017201150A1 (en) | 2016-05-18 | 2017-11-23 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as fxr agonists and methods of use thereof |
| WO2017201152A1 (en) | 2016-05-18 | 2017-11-23 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| CA2968836C (en) | 2016-06-13 | 2025-09-02 | Gilead Sciences Inc | Fxr (nr1h4) modulating compounds |
| CA3026512A1 (en) | 2016-06-13 | 2017-12-21 | Gilead Sciences, Inc. | Fxr (nr1h4) modulating compounds |
| TW201808283A (zh) | 2016-08-05 | 2018-03-16 | 廣東東陽光藥業有限公司 | 含氮三環化合物及其在藥物中的應用 |
| US11091482B2 (en) | 2016-08-23 | 2021-08-17 | Ardelyx, Inc. | Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators |
| MA55632A (fr) * | 2016-08-23 | 2022-02-16 | Ardelyx Inc | Procédé de preparation de modulateurs du récepteur hormonal pour le traitement d'états et de troubles métaboliques |
| KR20210110407A (ko) * | 2016-09-14 | 2021-09-07 | 노파르티스 아게 | Fxr 작용제의 신규 요법 |
| JP2019537557A (ja) * | 2016-10-04 | 2019-12-26 | エナンタ ファーマシューティカルズ インコーポレイテッド | Ｆｘｒアゴニストとしてのイソキサゾール類似体およびその使用方法 |
| US10597391B2 (en) | 2016-10-26 | 2020-03-24 | Enanta Pharmaceuticals, Inc. | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof |
| CN108017636A (zh) * | 2016-11-04 | 2018-05-11 | 合帕吉恩治疗公司 | 作为fxr调节剂的含氮杂环化合物 |
| CN108218852A (zh) * | 2016-12-15 | 2018-06-29 | 宁波百纳西药业有限公司 | 一种螺环化合物、其制备方法、组合物及用途 |
| EP4122464B1 (en) | 2017-03-28 | 2024-05-15 | Gilead Sciences, Inc. | Therapeutic combinations for treating liver diseases |
| US20210085662A1 (en) | 2017-03-30 | 2021-03-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for reducing persistence and expression of episomal viruses |
| NZ758117A (en) | 2017-04-12 | 2022-01-28 | Il Dong Pharma | Isoxazole derivatives as nuclear receptor agonists and uses thereof |
| CN109265471B (zh) * | 2017-06-30 | 2021-06-04 | 轩竹生物科技有限公司 | Fxr受体激动剂 |
| CN109320509B (zh) * | 2017-07-31 | 2022-02-08 | 轩竹生物科技股份有限公司 | Fxr受体激动剂 |
| WO2019055808A1 (en) | 2017-09-14 | 2019-03-21 | Ardelyx, Inc. | HORMONE RECEPTOR MODULATORS FOR THE TREATMENT OF MUTAGENIC AND FIBROTIC METABOLIC CONDITIONS AND DISORDERS |
| KR102731924B1 (ko) | 2017-11-01 | 2024-11-19 | 브리스톨-마이어스 스큅 컴퍼니 | 파르네소이드 x 수용체 조정제로서의 스피로시클릭 화합물 |
| KR102732404B1 (ko) * | 2017-11-01 | 2024-11-19 | 브리스톨-마이어스 스큅 컴퍼니 | 파르네소이드 x 수용체 조정제로서의 알켄 화합물 |
| JP7264905B2 (ja) | 2017-11-01 | 2023-04-25 | ブリストル－マイヤーズ スクイブ カンパニー | ファルネソイドｘ受容体モジュレーターとしての多環化合物 |
| SG11202003827YA (en) * | 2017-11-01 | 2020-05-28 | Bristol Myers Squibb Co | Bridged bicyclic compounds as farnesoid x receptor modulators |
| AU2018360575A1 (en) | 2017-11-01 | 2020-06-18 | Bristol-Myers Squibb Company | Alkene spirocyclic compounds as farnesoid X receptor modulators |
| US10689391B2 (en) | 2017-12-12 | 2020-06-23 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as FXR agonists and methods of use thereof |
| US11667629B2 (en) | 2017-12-22 | 2023-06-06 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Isoxazole derivative, preparation method therefor, and use thereof |
| CN110128432B (zh) | 2018-02-02 | 2021-03-02 | 广东东阳光药业有限公司 | 含氮三环化合物及其在药物中的应用 |
| WO2019160813A1 (en) | 2018-02-14 | 2019-08-22 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| CN110452235B (zh) * | 2018-05-08 | 2023-02-17 | 中国科学院上海药物研究所 | 一类含氟异噁唑类化合物及其制备方法、药物组合物和用途 |
| AU2018438845A1 (en) * | 2018-08-30 | 2021-04-01 | Terns Pharmaceuticals, Inc. | Treating liver disorders |
| CN111320609A (zh) | 2018-12-13 | 2020-06-23 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
| LT3911647T (lt) | 2019-01-15 | 2024-03-25 | Gilead Sciences, Inc. | Izoksazolo junginys kaip fxr agonistas ir jį apimančios farmacinės kompozicijos |
| US12479816B2 (en) | 2019-02-08 | 2025-11-25 | University of Pittsburgh—of the Commonwealth System of Higher Education | 20-HETE formation inhibitors |
| US12319676B2 (en) | 2019-02-15 | 2025-06-03 | Bristol-Myers Squibb Company | Substituted amide compounds useful as farnesoid X receptor modulators |
| EP3924329A2 (en) | 2019-02-15 | 2021-12-22 | Bristol-Myers Squibb Company | Substituted amide compounds useful as farnesoid x receptor modulators |
| JP7465883B2 (ja) | 2019-02-15 | 2024-04-11 | ブリストル－マイヤーズ スクイブ カンパニー | ファルネソイドｘ受容体モジュレータとしての置換二環式化合物 |
| AR118050A1 (es) | 2019-02-15 | 2021-09-15 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x |
| CA3129949C (en) | 2019-02-19 | 2024-04-30 | Gilead Sciences, Inc. | Solid forms of fxr agonists |
| SG11202111502XA (en) | 2019-04-19 | 2021-11-29 | Shanghai Institute Of Materia Medica Chinese Academy Of Sciences | Fxr small molecule agonist and preparation method therefor and use thereof |
| US11555032B2 (en) | 2019-05-13 | 2023-01-17 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| CA3142358A1 (en) | 2019-05-30 | 2020-12-03 | Intercept Pharmaceuticals, Inc. | Pharmaceutical compositions comprising a fxr agonist and a fibrate for use in the treatment of cholestatic liver disease |
| US20220241376A1 (en) | 2019-07-18 | 2022-08-04 | Enyo Pharma | Method for decreasing adverse-effects of interferon |
| US12398127B2 (en) | 2019-09-12 | 2025-08-26 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| IL292459A (en) * | 2019-11-08 | 2022-06-01 | Terns Pharmaceuticals Inc | Treatment of liver disorders |
| WO2021108974A1 (en) | 2019-12-03 | 2021-06-10 | Gannex Pharma Co., Ltd | Compounds for modulating activity of fxr and uses thereof |
| EP4090327B1 (en) | 2020-01-15 | 2025-03-05 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of fxr agonists for treating an infection by hepatitis d virus |
| EP4149452A4 (en) * | 2020-05-13 | 2024-05-01 | Terns Pharmaceuticals, Inc. | COMBINATION TREATMENT OF LIVER DISEASES |
| IL300853A (en) | 2020-08-25 | 2023-04-01 | Lilly Co Eli | Polymorphs of an ssao inhibitor |
| IL301238A (en) * | 2020-09-11 | 2023-05-01 | Terns Pharmaceuticals Inc | Solid dispersion formulations of an fxr agonist |
| EP4229043A4 (en) * | 2020-10-15 | 2025-01-08 | Eli Lilly and Company | POLYMORPHS OF AN FXR AGONIST |
| JP2024502673A (ja) | 2021-01-14 | 2024-01-22 | ウエヌイグレックオ・ファーマ | Ｈｂｖ感染の処置のためのｆｘｒアゴニストとｉｆｎの相乗効果 |
| CA3213217A1 (en) | 2021-04-28 | 2022-11-03 | Raphael Darteil | Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment |
| AU2022387121A1 (en) | 2021-11-11 | 2024-06-20 | Terns Pharmaceuticals, Inc. | Combination of a ssao inhibitor and thr-beta agonist for use in the treatment of liver disorders |
| WO2023220404A1 (en) * | 2022-05-13 | 2023-11-16 | Terns Pharmaceuticals, Inc. | Treatment of non-alcoholic steatohepatitis |
| CN115850152B (zh) * | 2022-12-20 | 2025-10-31 | 河北鼎泰制药有限公司 | 一种杂质A-7-imp3的制备方法及其用途 |
| EP4568664A1 (en) | 2023-04-07 | 2025-06-18 | Terns Pharmaceuticals, Inc. | Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating a liver disorder or a cardiometabolic disease |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07138258A (ja) | 1993-11-16 | 1995-05-30 | Taiho Yakuhin Kogyo Kk | チアゾリジンジオン誘導体又はその塩 |
| JP2002532729A (ja) | 1998-12-23 | 2002-10-02 | グラクソ グループ リミテッド | 核内受容体のリガンドのアッセイ |
| US7105556B2 (en) | 2001-05-30 | 2006-09-12 | Bristol-Myers Squibb Company | Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method |
| US6967212B2 (en) * | 2001-05-30 | 2005-11-22 | Bristol-Myers Squibb Company | Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method |
| EP1285914B1 (en) | 2001-08-13 | 2007-12-19 | PheneX Pharmaceuticals AG | Nr1h4 nuclear receptor binding compounds |
| JP4541883B2 (ja) | 2002-07-09 | 2010-09-08 | ブリストル−マイヤーズ スクイブ カンパニー | 抗糖尿病薬および抗肥満症薬として有用な置換へテロ環誘導体、並びに方法 |
| AU2003290700A1 (en) * | 2002-11-22 | 2004-06-18 | Smithkline Beecham Corporation | Farnesoid x receptor agonists |
| EP1984360B1 (en) | 2006-02-03 | 2014-01-15 | Eli Lilly & Company | Compounds and methods for modulating FX-receptors |
| PL2029547T3 (pl) * | 2006-05-24 | 2010-09-30 | Lilly Co Eli | Agoniści FXR |
| ATE460403T1 (de) * | 2006-05-24 | 2010-03-15 | Lilly Co Eli | Verbindungen und verfahren zur modulierung von fx-rezeptoren |
-
2008
- 2008-07-03 TW TW097125064A patent/TW200906823A/zh unknown
- 2008-07-11 EA EA201070148A patent/EA016475B1/ru not_active IP Right Cessation
- 2008-07-11 PE PE2008001168A patent/PE20090809A1/es not_active Application Discontinuation
- 2008-07-11 BR BRPI0814571-7A2A patent/BRPI0814571A2/pt not_active IP Right Cessation
- 2008-07-11 WO PCT/US2008/069719 patent/WO2009012125A1/en not_active Ceased
- 2008-07-11 US US12/600,879 patent/US8153624B2/en active Active
- 2008-07-11 PT PT08781651T patent/PT2178851E/pt unknown
- 2008-07-11 SI SI200830514T patent/SI2178851T1/sl unknown
- 2008-07-11 JP JP2010517082A patent/JP5373788B2/ja active Active
- 2008-07-11 HR HR20120048T patent/HRP20120048T1/hr unknown
- 2008-07-11 MX MX2010000502A patent/MX2010000502A/es active IP Right Grant
- 2008-07-11 AU AU2008276236A patent/AU2008276236B2/en not_active Ceased
- 2008-07-11 EP EP08781651A patent/EP2178851B1/en active Active
- 2008-07-11 CN CN2008800247651A patent/CN101743232B/zh active Active
- 2008-07-11 PL PL08781651T patent/PL2178851T3/pl unknown
- 2008-07-11 DK DK08781651.8T patent/DK2178851T3/da active
- 2008-07-11 AT AT08781651T patent/ATE539065T1/de active
- 2008-07-11 ES ES08781651T patent/ES2376176T3/es active Active
- 2008-07-11 RS RS20120099A patent/RS52216B/sr unknown
- 2008-07-11 KR KR1020107000896A patent/KR101157334B1/ko not_active Expired - Fee Related
- 2008-07-11 CA CA2693406A patent/CA2693406C/en not_active Expired - Fee Related
- 2008-07-14 AR ARP080103026A patent/AR067540A1/es not_active Application Discontinuation
- 2008-07-14 CL CL2008002051A patent/CL2008002051A1/es unknown
-
2009
- 2009-11-19 IL IL202234A patent/IL202234A0/en unknown
-
2010
- 2010-01-12 CO CO10002335A patent/CO6270212A2/es not_active Application Discontinuation
- 2010-01-12 DO DO2010000018A patent/DOP2010000018A/es unknown
- 2010-01-15 TN TNP2010000028A patent/TN2010000028A1/fr unknown
- 2010-01-15 EC EC2010009879A patent/ECSP109879A/es unknown
- 2010-01-15 SV SV2010003458A patent/SV2010003458A/es not_active Application Discontinuation
- 2010-02-11 MA MA32615A patent/MA31683B1/fr unknown
-
2012
- 2012-01-27 CY CY20121100098T patent/CY1112298T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2376176T3 (es) | Compuestos y procedimientos para modular fxr. | |
| ES2452031T3 (es) | Compuestos y procedimientos para modular receptores FX | |
| ES2255294T3 (es) | Derivados de isoxazol sustituidos como moduladores del receptor de estrogenos. | |
| DK2467366T3 (en) | New FXR (NR1H4) Binding and Activity Modulating Compounds | |
| TWI445705B (zh) | 經苯基及苯并二基取代之吲唑衍生物 | |
| CN102958925B (zh) | 吡唑衍生物钙释放激活钙通道调节剂及非小细胞肺癌的治疗方法 | |
| TWI705966B (zh) | 新穎的三唑并[4,5-d]嘧啶衍生物 | |
| TWI304066B (en) | Indole compounds | |
| CA2651373A1 (en) | Compounds and methods for modulating fxr | |
| EA015632B1 (ru) | Агонисты fxr | |
| WO2004013135A1 (en) | 2-phenylpyridin-4-yl derivatives as alk5 inhibitors | |
| JP2007084548A (ja) | 置換されたアリールチオウレアおよび関連化合物；ウイルス複製のインヒビター | |
| US11052092B2 (en) | N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)acetamide derivatives and related compounds as ROR-gamma modulators for treating autoimmune diseases | |
| WO2015024448A1 (zh) | 苯并哌啶环与苯并吗啉环类化合物、其制法及医药应用 | |
| BR112018011562B1 (pt) | Novos derivados de fenil | |
| KR20100091201A (ko) | 페닐-옥세타닐-유도체 | |
| ES2324674T3 (es) | Derivados de fenilpirazol como activadores de ppar. | |
| JP2023545677A (ja) | Ｆｘｒ小分子アゴニストとその調製方法および用途 | |
| ES2342222T3 (es) | Agonistas de fxr. | |
| TWI855100B (zh) | 新型細胞凋亡訊號調節激酶1抑制劑 | |
| HK40084541B (en) | Fxr (nr1h4) modulating compounds | |
| CN106604917A (zh) | 作为醛固酮合酶抑制剂的新型二氢喹啉吡唑基化合物 |